Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
Year: 2022
Type: article
Source: Blood
Institutions: Washington University in St. Louis, Banner MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Stanford University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, University of Rochester Medicine, University of Rochester, The University of Kansas Cancer Center, Dana-Farber Cancer Institute, Amsterdam University Medical Centers, University of Amsterdam, Tel Aviv University, Tel Aviv Sourasky Medical Center, Vanderbilt University, Vanderbilt University Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310117634